Back to results
US 5,508,300 AGranted
Dihydro pyrazolopyrroles, compositions and use
AssigneePfizer Inc.
InventorAllen J. Duplantier
Life of this patent
Estimating the term…
Abstract
The compounds of the formula ##STR1## and the pharmaceutically acceptable salts thereof; wherein X.sub.1, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein, are inhibitors of PDE IV and the production of tumor necrosis factor. As such, they are active in the treatment of inflammatory diseases, shock etc.
Claims15
A compound of the formula ##STR7## or pharmaceutically acceptable salts thereof;
- wherein X is oxygen;
- R.sup.1 is C.sub.1 -C.sub.7 alkyl, C.sub.2 -C.sub.3 alkenyl, phenyl, C.sub.3 -C.sub.5 cycloalkyl or methylene(C.sub.3 -C.sub.5 cycloalkyl) wherein each alkyl, phenyl or alkenyl group may be substituted with one or two methyl, ethyl or trifluoromethyl, or up to three halogens;
- R.sup.2 is hydrogen;
- C.sub.2 -C.sub.14 alkyl;
- (C.sub.1 -C.sub.7 alkoxy) (C.sub.1 -C.sub.7 alkyl)--;
- C.sub.2 -C.sub.14 alkenyl;
- --(CH.sub.2).sub.n (C.sub.3 -C.sub.5 cycloalkyl) wherein n is 0, 1 or 2;
- a (CH.sub.2).sub.n (C.sub.4 -C.sub.7 heterocyclic group) wherein n is 0, 1 or 2, containing as the heteroatom one of oxygen, sulphur, sulphonyl or NR.sup.5 wherein R.sup.5 is hydrogen, or C.sub.1 -C.sub.4 alkyl;
- or a group of the formula ##STR8## wherein a is an integer from 1 to 4;
- b and c are 0 or 1;
- R.sup.6 is hydrogen, hydroxy, C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.5 alkenyl, C.sub.1 -C.sub.5 alkoxy, C.sub.3 -C.sub.6 cycloalkoxy, halogen, trifluoromethyl, nitro, CO.sub.2 R.sup.7, CONR.sup.7 R.sup.8, NR.sup.7 R.sup.8, or SO.sub.2 NR.sup.7 R.sup.8 wherein R.sup.7 and R.sup.8 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl;
- Z is oxygen, sulphur, sulphonyl or NR.sup.9 wherein R.sup.9 is hydrogen or C.sub.1 -C.sub.4 alkyl;
- and Y is C.sub.1 -C.sub.5 alkylene or C.sub.2 -C.sub.6 alkenylene which may be substituted with one or two C.sub.1 -C.sub.7 alkyl or C.sub.3 -C.sub.7 cycloakyl;
- wherein each said alkyl, alkenyl, cycloalkyl, alkoxyalkyl or heterocyclic group may be substituted with one to fourteen substituents R.sub.10 selected from the group consisting of methyl, ethyl, trifluoromethyl and halogen;
- R.sub.3 is C.sub.1 -C.sub.14 alkyl;
- (C.sub.1 -C.sub.7 alkoxy) (C.sub.1 -C.sub.7 alkyl)--;
- C.sub.2 -C.sub.14 alkenyl;
- --(CH.sub.2).sub.n (C.sub.3 -C.sub.5 cycloalkyl) wherein n is 0, 1 or 2;
- a (CH.sub.2).sub.n (C.sub.4 -C.sub.7 heterocyclic group) wherein n is 0, 1 or 2, containing as the heteroatom one of oxygen, sulphur, sulphonyl or NR.sup.5 wherein R.sup.5 is hydrogen, or C.sub.1 -C.sub.4 alkyl;
- or a group of the formula ##STR9## wherein a is an integer from 1 to 4;
- b and c are 0 or 1;
- R.sup.6 is hydrogen, hydroxy, C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.5 alkenyl, C.sub.1 -C.sub.5 alkoxy, C.sub.3 -C.sub.6 cycloalkoxy, halogen, trifluoromethyl, nitro, CO.sub.2 R.sup.7, CONR.sup.7 R.sup.8, NR.sup.7 R.sup.8 , or SO.sub.2 NR.sup.7 R.sup.8 wherein R.sup.7 and R.sup.8 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl;
- Z is oxygen, sulphur, sulphonyl or NR.sup.9 wherein R.sup.9 is hydrogen or C.sub.1 -C.sub.4 alkyl;
- and Y is C.sub.1 -C.sub.5 alkylene or C.sub.2 -C.sub.6 alkenylene which may be substituted with one or two C.sub.1 -C.sub.7 alkyl or C.sub.3 -C.sub.7 cycloakyl;
- wherein each said alkyl, alkenyl, cycloalkyl, alkoxyalkyl or heterocyclic group may be substituted with one to fourteen substituents R.sub.10 selected from the group consisting of methyl, ethyl, trifluoromethyl and halogen;
- R.sup.4 is hydrogen, C.sub.1 -C.sub.7 alkyl, C.sub.3 -C.sub.5 cycloalkyl, or methylene (C.sub.3 -C.sub.5 cycloalkyl) wherein each alkyl group may be substituted with one or two methyl, ethyl or trifluoromethyl, or up to three halogens.
23 more elements
A compound according to claim I wherein R.sup.3 is C.sub.1 -C.sub.6 alkyl;
- phenyl substituted by one or two halogen;
- cyclopentyl, or methylenecyclopropyl.
A method for the inhibition of phospho-diesterase (PDE) type IV and the production of tumor necrosis factor (TNF) comprising administering to a patient an effective amount of a compound of the formula ##STR10## or pharmaceutically acceptable salts thereof;
- wherein X is oxygen;
- R.sup.1 is hydrogen, C.sub.1 -C.sub.7 alkyl, C.sub.2 -C.sub.3 alkenyl, phenyl, C.sub.3 -C.sub.5 cycloakyl or methylene(C.sub.3 -C.sub.5 cycloalkyl) wherein each alkyl, phenyl or alkenyl group may be substituted with one or two methyl, ethyl or trifluoromethyl, or up to three halogens;
- R.sup.2 and R.sup.3 are each independently selected from the group consisting of hydrogen;
- C.sub.1 -C.sub.14 alkyl;
- (C.sub.1 -C.sub.7 alkoxy) (C.sub.1 -C.sub.7 alkyl)--;
- C.sub.2 -C.sub.14 alkenyl;
- --(CH.sub.2).sub.n (C.sub.3 -C.sub.5 cycloakyl) wherein n is 0, 1 or 2;
- a (CH.sub.2).sub.n (C.sub.4 -C.sub.7 heterocyclic group) wherein n is 0, 1 or 2, containing as the heteroatom one of oxygen, sulphur, sulphonyl or NR.sup.5 wherein R.sup.5 is hydrogen, or C.sub.1 -C.sub.4 alkyl;
- or a group of the formula ##STR11## wherein a is an integer from 1 to 4;
- b and c are 0 or 1;
- R.sup.6 is hydrogen, hydroxy, C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.5 alkenyl, C.sub.1 -C.sub.5 alkoxy, C.sub.3 -C.sub.6 cycloalkoxy, halogen, trifluoromethyl, nitro, CO.sub.2 R.sup.7, CONR.sup.7 R.sup.8, NR.sup.7 R.sup.8, or SO.sub.2 NR.sup.7 R.sup.8 wherein R.sup.7 and R.sup.8 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl;
- Z is oxygen, sulphur, sulphonyl or NR.sup.9 wherein R.sup.9 is hydrogen or C.sub.1 -C.sub.4 alkyl;
- and Y is C.sub.1 -C.sub.5 alkylene or C.sub.2 -C.sub.6 alkenylene which may be substituted with one or two C.sub.1 -C.sub.7 alkyl or C.sub.3 -C.sub.7 cycloakyl;
- wherein each said alkyl, alkenyl, cycloalkyl, alkoxyalkyl or heterocyclic group may be substituted with one to fourteen substituents R.sub.10 selected from the group consisting of methyl, ethyl, trifluoromethyl and halogen;
- and
- R.sup.4 is hydrogen, C.sub.1 -C.sub.7 alkyl, phenyl, C.sub.3 -C.sub.5 cycloalkyl, or methylene (C.sub.3 -C.sub.5 cycloalkyl) wherein each alkyl or phenyl group may be substituted with one or two methyl, ethyl or trifluoromethyl, or up to three halogens.
13 more elements
A pharmaceutical composition for the inhibition of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) comprising a pharmaceutically effective amount of a compound of the formula ##STR12## or pharmaceutically acceptable salts thereof;
- wherein X is oxygen;
- R.sup.1 is hydrogen, C.sub.1 -C.sub.7 alkyl, C.sub.2 -C.sub.3 alkenyl, phenyl, C.sub.3 -C.sub.5 cycloakyl or methylene(C.sub.3 -C.sub.5 cycloalkyl) wherein each alkyl, phenyl or alkenyl group may be substituted with one or two methyl, ethyl or trifluoromethyl, or up to three halogens;
- R.sup.2 and R.sup.3 are each independently selected from the group consisting of hydrogen;
- C.sub.1 -C.sub.14 alkyl;
- (C.sub.1 -C.sub.7 alkoxy) (C.sub.1 -C.sub.7 alkyl)--;
- C.sub.2 -C.sub.14 alkenyl;
- --(CH.sub.2).sub.n (C.sub.3 -C.sub.5 cycloalkyl) wherein n is 0, 1 or 2;
- a (CH.sub.2).sub.n (C.sub.4 -C.sub.7 heterocyclic group) wherein n is 0, 1 or 2, containing as the heteroatom one of oxygen, sulphur, sulphonyl or NR.sup.5 wherein R.sup.5 is hydrogen, or C.sub.1 -C.sub.4 alkyl;
- or a group of the formula ##STR13## wherein a is an integer from 1 to 4;
- b and c are 0 or 1;
- R.sup.6 is hydrogen, hydroxy, C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.5 alkenyl, C.sub.1 -C.sub.5 alkoxy, C.sub.3 -C.sub.6 cycloalkoxy, halogen, trifluoromethyl, nitro, CO.sub.2 R.sup.7, CONR.sup.7 R.sup.8, NR.sup.7 R.sup.8, or SO.sub.2 NR.sup.7 R.sup.8 wherein R.sup.7 and R.sup.8 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl;
- Z is oxygen, sulphur, sulphonyl or NR.sup.9 wherein R.sup.9 is hydrogen or C.sub.1 -C.sub.4 alkyl;
- and Y is C.sub.1 -C.sub.5 alkylene or C.sub.2 -C.sub.6 alkenylene which may be substituted with one or two C.sub.1 -C.sub.7 alkyl or C.sub.3 -C.sub.7 cycloakyl;
- wherein each said alkyl, alkenyl, cycloalkyl, alkoxyalkyl or heterocyclic group may be substituted with one to fourteen substituents R.sub.10 selected from the group consisting of methyl, ethyl, trifluoromethyl and halogen;
- and
- R.sup.4 is hydrogen, C.sub.1 -C.sub.7 alkyl, phenyl, C.sub.3 -C.sub.5 cycloalkyl, or methylene (C.sub.3 -C.sub.5 cycloalkyl) wherein each alkyl or phenyl group may be substituted with one or two methyl, ethyl or trifluoromethyl, or up to three halogens, in admixture with a pharmaceutical carrier selected from the group consisting of tablets, capsules, elixirs, sterile parenteral solutions, creams, jellies, gels, pastes and ointments.
13 more elements
Dependencies are inferred from the claim text.